ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

3:00PM-3:50PM: Abstract Number: 1973

Treatment Sequences with Romosozumab Before or After Antiresorptive Medication

Osteoporosis & Metabolic Bone Disease (1973–1977)

3:00PM-3:50PM: Abstract Number: 1974

Validation of a Deep Learning Based Algorithm to Diagnose Vertebral Compression Fractures

Osteoporosis & Metabolic Bone Disease (1973–1977)

4:00PM-4:50PM: Abstract Number: 2042

A Low FODMAP Diet Is Not Associated with Decreased GI Symptoms or Changes in GI Microbial Composition in Patients with Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical II: Lessons Learned from Clinical Trials & Cohorts (2038–2042)

4:00PM-4:50PM: Abstract Number: 2038

Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis

Systemic Sclerosis & Related Disorders – Clinical II: Lessons Learned from Clinical Trials & Cohorts (2038–2042)

4:00PM-4:50PM: Abstract Number: 2004

Circulating Biomolecules as Potential Biomarkers of Early and Establishedresponse to TNFi Therapy in Rheumatoid Arthritis Patients

RA – Treatments III: Predictors of Treatment Response (2003–2007)

4:00PM-4:50PM: Abstract Number: 2040

Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON

Systemic Sclerosis & Related Disorders – Clinical II: Lessons Learned from Clinical Trials & Cohorts (2038–2042)

4:00PM-4:50PM: Abstract Number: 2041

Disease Features of Systemic Sclerosis Are Associated with Alterations in Gastrointestinal Microbial Composition in Two Independent Cohorts

Systemic Sclerosis & Related Disorders – Clinical II: Lessons Learned from Clinical Trials & Cohorts (2038–2042)

4:00PM-4:50PM: Abstract Number: 2005

Histo-pathological Cellular Markers of Treatment Response to Rituximab and Tocilizumab in Matched Pre- and Post-treatment Synovial Biopsies from the R4RA Randomised Clinical Trial in Rheumatoid Arthritis

RA – Treatments III: Predictors of Treatment Response (2003–2007)

4:00PM-4:50PM: Abstract Number: 2006

Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data

RA – Treatments III: Predictors of Treatment Response (2003–2007)

4:00PM-4:50PM: Abstract Number: 2003

Individualized Prediction of Response to Methotrexate Treatment in Patients with Rheumatoid Arthritis: A Pharmacogenomics-driven Machine Learning Approach

RA – Treatments III: Predictors of Treatment Response (2003–2007)

4:00PM-4:50PM: Abstract Number: 2028

Predictors of Maintaining Inactive Disease After Etanercept Withdrawal, and Regaining Inactive Disease Status After Flare and Retreatment, in Adults with Non-radiographic Axial Spondyloarthritis: Results from RE-EMBARK

Spondyloarthritis Including Psoriatic Arthritis – Treatment III: Axial Spondyloarthritis (2028–2032)

4:00PM-4:50PM: Abstract Number: 2039

Short Telomeres and Autoantibodies Targeting Telomere-Associated Proteins in Scleroderma

Systemic Sclerosis & Related Disorders – Clinical II: Lessons Learned from Clinical Trials & Cohorts (2038–2042)

4:00PM-4:50PM: Abstract Number: 2029

Therapeutic Drug Monitoring Compared to Standard Treatment of Patients Starting Infliximab: Results from a Multicenter Randomized Controlled Trial of 400 Patients

Spondyloarthritis Including Psoriatic Arthritis – Treatment III: Axial Spondyloarthritis (2028–2032)

4:00PM-4:50PM: Abstract Number: 2032

Treatment Response to Biological Disease-modifying Anti-rheumatic Drugs Is Associated with Favorable Changes of the Body Composition in Patients with Ankylosing Spondylitis

Spondyloarthritis Including Psoriatic Arthritis – Treatment III: Axial Spondyloarthritis (2028–2032)

4:00PM-4:50PM: Abstract Number: 2030

Treatment with Selective Cyclooxygenase-2 Inhibitors Is Associated with Inhibition of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort

Spondyloarthritis Including Psoriatic Arthritis – Treatment III: Axial Spondyloarthritis (2028–2032)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].